Morgan Stanley Cuts Certara (NASDAQ:CERT) Price Target to $10.00

Certara (NASDAQ:CERT) had its price target reduced by analysts at Morgan Stanley from $11.00 to $10.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Morgan Stanley’s target price suggests a potential upside of 94.93% from the stock’s previous close.

Other research analysts have also issued reports about the stock. Barclays reissued an “equal weight” rating and set a $8.00 target price on shares of Certara in a research note on Friday, March 6th. TD Cowen reissued a “buy” rating on shares of Certara in a research note on Thursday, February 26th. KeyCorp cut their target price on shares of Certara from $10.00 to $8.00 and set an “overweight” rating on the stock in a research note on Monday, April 13th. Robert W. Baird cut their target price on shares of Certara from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Tuesday. Finally, Wall Street Zen lowered shares of Certara from a “buy” rating to a “hold” rating in a research note on Sunday, February 15th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $9.80.

Certara Trading Down 18.7%

CERT opened at $5.13 on Tuesday. Certara has a twelve month low of $4.99 and a twelve month high of $13.88. The company has a quick ratio of 2.05, a current ratio of 2.05 and a debt-to-equity ratio of 0.27. The company has a fifty day moving average of $6.21 and a 200-day moving average of $8.01. The stock has a market cap of $786.53 million, a PE ratio of -513.00 and a beta of 1.53.

Certara (NASDAQ:CERT) last issued its earnings results on Monday, May 11th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.02). The company had revenue of $106.92 million for the quarter, compared to the consensus estimate of $106.13 million. Certara had a positive return on equity of 4.20% and a negative net margin of 0.38%.The firm’s revenue was up .8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.14 earnings per share. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. On average, sell-side analysts predict that Certara will post 0.29 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Associated Banc Corp lifted its stake in shares of Certara by 9.7% in the third quarter. Associated Banc Corp now owns 11,920 shares of the company’s stock valued at $146,000 after buying an additional 1,051 shares in the last quarter. Versant Capital Management Inc lifted its stake in shares of Certara by 66.7% in the third quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock valued at $35,000 after buying an additional 1,153 shares in the last quarter. Osaic Holdings Inc. lifted its stake in shares of Certara by 50.7% in the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after buying an additional 1,175 shares in the last quarter. Corient Private Wealth LLC lifted its stake in shares of Certara by 11.7% in the second quarter. Corient Private Wealth LLC now owns 12,362 shares of the company’s stock valued at $144,000 after buying an additional 1,295 shares in the last quarter. Finally, Treasurer of the State of North Carolina lifted its stake in shares of Certara by 2.9% in the second quarter. Treasurer of the State of North Carolina now owns 56,628 shares of the company’s stock valued at $663,000 after buying an additional 1,597 shares in the last quarter. 73.96% of the stock is owned by institutional investors.

Trending Headlines about Certara

Here are the key news stories impacting Certara this week:

• Neutral Sentiment: Certara said its AI investments are intended to support long-term growth, which could help the company’s platform and future revenue opportunities. Certara says AI investments will drive long-term growth – but traders are focused on one warning
• Neutral Sentiment: The company reported quarterly revenue of $106.92 million, slightly ahead of expectations, showing modest top-line growth despite mixed overall results. Certara Reports First Quarter 2026 Financial Results
• Negative Sentiment: Adjusted EPS of $0.09 missed the $0.11 consensus estimate, reinforcing concerns that earnings momentum is weaker than expected. Certara, Inc. (CERT) Q1 Earnings Miss Estimates
• Negative Sentiment: Management cut FY 2026 guidance to EPS of $0.350-$0.410 and revenue of $395 million-$405 million, both below Wall Street forecasts, which appears to be the main reason the stock is falling. Certara (CERT) shares slide after weak full-year guidance overshadows revenue beat
• Negative Sentiment: The earnings miss and weaker outlook helped push CERT to a new 52-week low, and the stock was even halted briefly during trading due to a LULD pause, highlighting elevated volatility. Certara (NASDAQ:CERT) Hits New 52-Week Low After Earnings Miss

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.